Symlin

Type 1 Diabetes, Type 2 Diabetes
Treatment
4 FDA approvals
20 Active Studies for Symlin

What is Symlin

PramlintideThe Generic name of this drug
Treatment SummaryPramlintide is a newly developed diabetes medication created by Amylin Pharmaceuticals. It helps to regulate blood sugar levels by supplementing the hormone amylin, which is usually present in the bloodstream after meals but is deficient in those with diabetes. Pramlintide can be used to treat both type 1 and type 2 diabetes.
SymlinPenis the brand name
image of different drug pills on a surface
Symlin Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
SymlinPen
Pramlintide
2005
6

Approved as Treatment by the FDA

Pramlintide, also known as SymlinPen, is approved by the FDA for 4 uses including Type 2 Diabetes Mellitus and Type 1 Diabetes Mellitus .
Type 2 Diabetes Mellitus
Helps manage Type 2 Diabetes Mellitus
Type 1 Diabetes Mellitus
Helps manage Type 1 Diabetes Mellitus
Type 1 Diabetes
Helps manage Type 1 Diabetes Mellitus
Type 2 Diabetes
Helps manage Type 2 Diabetes Mellitus

Effectiveness

How Symlin Affects PatientsPramlintide is a synthetic hormone-like drug that is meant to replace amylin, a hormone produced by the pancreas that helps regulate sugar levels. People with diabetes often don't have enough amylin in their body. Pramlintide is a chain of 37 amino acids, three of which are different than the amino acids found in human amylin. It is available in the form of an acetate salt.
How Symlin works in the bodyPramlintide is a drug that imitates the effects of the pancreatic hormone amylin in the body. Amylin helps control blood sugar levels, and pramlintide works in the same way. It does this by slowing down the stomach's emptying rate, reducing the body's production of glucagon, and making the user feel fuller, which helps reduce calorie intake and leads to weight loss. Pramlintide attaches to three different receptor complexes in the body, all of which contain the calcitonin receptor and one of three Receptor activity-modifying proteins.

When to interrupt dosage

The recommended dosage of Symlin is contingent upon the identified disorder. The amount of dosage shifts, based on the method of administration (e.g. Injection or Injection - Subcutaneous) listed in the table beneath.
Condition
Dosage
Administration
Type 2 Diabetes
, 1.0 mg/mL, 0.6 mg/mL
, Subcutaneous, Injection, Injection - Subcutaneous
Type 1 Diabetes
, 1.0 mg/mL, 0.6 mg/mL
, Subcutaneous, Injection, Injection - Subcutaneous

Warnings

There are 20 known major drug interactions with Symlin.
Common Symlin Drug Interactions
Drug Name
Risk Level
Description
Aclidinium
Major
The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Aclidinium.
Amitriptyline
Major
The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Amitriptyline.
Amoxapine
Major
The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Amoxapine.
Anisotropine methylbromide
Major
The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Anisotropine methylbromide.
Aripiprazole
Major
The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Aripiprazole.
image of a doctor in a lab doing drug, clinical research

Symlin Novel Uses: Which Conditions Have a Clinical Trial Featuring Symlin?

300 active trials are being conducted to assess the potential of Symlin in managing symptoms associated with Type 2 Diabetes.
Condition
Clinical Trials
Trial Phases
Type 1 Diabetes
190 Actively Recruiting
Phase 3, Not Applicable, Phase 2, Early Phase 1, Phase 1, Phase 4
Type 2 Diabetes
167 Actively Recruiting
Not Applicable, Phase 1, Phase 2, Phase 3, Phase 4, Early Phase 1

Symlin Reviews: What are patients saying about Symlin?

5Patient Review
6/1/2010
Symlin for Additional Medication for Diabetes Type 2
Symlin has helped me lose 95 pounds in less than a year, and I continue to see benefits from it. My insulin usage has decreased by 150 units per day on average.
5Patient Review
9/20/2015
Symlin for Additional Medication for Diabetes Type 1
I've seen vast improvements in my health since using this treatment, both physically and mentally. I highly recommend it to others.
5Patient Review
12/9/2009
Symlin for Additional Medication for Diabetes Type 2
I experienced nausea, vomiting, and sweats. My blood sugar also dropped significantly.
5Patient Review
10/16/2008
Symlin for Additional Medication for Diabetes Type 2
4Patient Review
12/29/2010
Symlin for Additional Medication for Diabetes Type 2
The price is the only downside to this pen, which otherwise works great. I don't know how they expect people to keep paying $300 a month, so I'll have to look for a different medication.
4Patient Review
2/26/2008
Symlin for Additional Medication for Diabetes Type 2
3.3Patient Review
8/17/2022
Symlin for Additional Medication for Diabetes Type 1
I've been using the symlin pen for years, but lately I've had six pens jam up on me, leaving 1/3 of the insulin inaccessible. I changed the pen needles many times, to no avail. Now I have three expired pens with dates from May/June 2023. My pharmacy (Walgreens) won't replace them, so now I'm short on my insulin supply.
2.7Patient Review
11/17/2014
Symlin for Additional Medication for Diabetes Type 2
I'm disappointed because I haven't seen any results after a week of use. My weight and sugar levels are the same. The good news is that I haven't experienced any side effects.
2.7Patient Review
8/17/2010
Symlin for Additional Medication for Diabetes Type 2
I've been using symlin for a while now, and it hasn't had any impact on my blood sugar levels. I'm starting to lose hope that this drug will have any benefits for me.
2.7Patient Review
9/1/2009
Symlin for Additional Medication for Diabetes Type 2
Didn't find this to be very helpful in terms of my appetite, which is why my doctor prescribed it.
2Patient Review
11/9/2009
Symlin for Additional Medication for Diabetes Type 2
I didn't see much difference when I was using this medication, but as soon as I stopped taking it, I gained 60 pounds. Once I started taking it again, the weight gain stopped. While it's not a "miracle" drug that causes you to lose a lot of weight, it does seem to help control your weight if you're consistent with taking it.
1.7Patient Review
4/22/2009
Symlin for Additional Medication for Diabetes Type 2
I began using Symlin a few weeks ago, injecting 60mcg 3 times per day. I didn't really see much of a difference. However, I recently upped my dosage to 120 mcg 3 times per day and have noticed significantly better blood sugar levels.
1.3Patient Review
9/11/2012
Symlin for Additional Medication for Diabetes Type 1
It's difficult to tell if this actually injected anything, as it frequently jammed on me. The injection caps are also incredibly annoying and wasteful; I had to throw away so many of them. On top of that, I experienced severe hypoglycemia several times while using this product. All in all, it has a steep learning curve and can be dangerous if not used properly.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about symlin

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the side effects of Symlin?

"Nausea, vomiting, lack of appetite, headache, joint pain, fatigue, allergic reaction, and dizziness are all side effects that can occur when taking this medication."

Answered by AI

Does Symlin cause weight loss?

"Symlin can help with weight loss by making people eat less food overall and snack less often. On average, people who use Symlin lose 6.6 pounds in the first six months."

Answered by AI

Is Symlin still on the market?

"There is no version of Symlin that is equivalent to what is available in the United States currently. There are online pharmacies that may try to sell a generic version of Symlin, but these could be counterfeit and potentially unsafe."

Answered by AI

What is the function of Symlin?

"The medication Symlin (pramlintide) can help to lower blood sugar in cases where fast-acting or mealtime insulin isn't enough. However, it can also cause blood sugar levels to drop dangerously low. This medication is used in addition to mealtime insulin, and is injected under the skin before major meals."

Answered by AI

Clinical Trials for Symlin

Image of Stanford University in Palo Alto, United States.

Decision Support Tool for Type 1 Diabetes

18 - 60
All Sexes
Palo Alto, CA
This study evaluates a digital decision-support tool designed to help individuals with type 1 diabetes prepare for exercise. This netIOB \& Exercise Tool (NEXT) uses glucose data and insulin delivery history to recommend individualized strategies such as carbohydrate intake, insulin adjustments, or delays in exercise start time. Participants will complete three structured aerobic or mixed-exercise sessions using different guidance approaches: (A) published consensus-based standard-of-care guidelines (B) usual personal care routines (C) the NEXT tool The study compares glucose outcomes, safety, and carbohydrate use across these conditions to inform better exercise preparation and support tools for people with diabetes.
Waitlist Available
Has No Placebo
Stanford UniversityRayhan Lal, MD
Image of University of California, Los Angeles in Los Angeles, United States.

Tailored DPP for Prediabetes

17 - 25
All Sexes
Los Angeles, CA
The goal of this study is to enhance reach and uptake of diabetes prevention among young adults, with a focus on recruiting underserved and high-need students who face additional challenges, including food and financial insecurity. The specific aims are: Aim 1 - Evaluate the efficacy of an AYA-tailored version of the UC DPP for mitigating type 2 diabetes risk (i.e., weight change) in a pre/post pilot trial. The investigators hypothesize that the AYA-tailored intervention will be effective at producing 5% weight loss from baseline to program completion (at 9-months). Aim 2 - Assess the feasibility and acceptability of an AYA-tailored version of the UC DPP program. The investigators hypothesize that it will be feasible to recruit the desired number of participants given proposed innovative outreach strategies, and that the AYA-tailored intervention will be deemed acceptable to participants both qualitatively and in regards to their retention in the program at rates similar to the larger UC DPP. The investigators will recruit 80 UCLA undergraduate students. Participants will be asked to complete a brief screening online form to assess eligibility and to collect contact information. The PI and/or Research Assistants (RAs) will reach out to eligible participants to obtain informed consent and enroll them in the pilot trial. The investigators will randomize participants to the tailored DPP cohort vs control cohort. Control participants will be offered the opportunity to participate in the tailored DPP in the following academic year. The tailored DPP intervention will be online and asynchronously. Participants will be asked to complete the intervention lessons on their own time. Each lesson typically takes on average 15 minutes to complete. Control group will receive each intervention materials via e-mail for participants to review on their own time and will receive acceptability surveys. The interventions for the control group will be remote. A research assistant will meet with control participants via Zoom to explain the intervention materials. Control group will receive access to a study habits intervention, alcohol use intervention, and financial literacy intervention. At the end of each quarter (Fall, Winter, and Spring), both control and intervention participants will receive an email with a unique link to a brief REDCap survey to ascertain acceptability of sessions/lessons. Furthermore, participants will complete baseline and 9-month follow-up assessments. Participants will complete a 30 minute questionnaire and height/weight measurements will be collected by a RA. Participants will be asked to self-report weight and physical activity at the end of the fall and winter quarter; data will be collected via brief REDCap survey.
Recruiting
Has No Placebo
University of California, Los AngelesLauren E Wisk, PhD
Image of Medpace Clinical Pharmaology Unit in Cincinnati, United States.

PATAS for Type 2 Diabetes

18 - 55
All Sexes
Cincinnati, OH
The primary objective of Part 1 of this study is to evaluate safety and tolerability of single subcutaneous (SC) doses of PATAS in healthy subjects. The secondary objective of Part 1 of this study is to determine the pharmacokinetics (PK) of single SC doses of PATAS in healthy subjects. The primary objectives of Part 2 of this study are to evaluate the safety and tolerability of 4 weekly SC doses of PATAS in subjects with T2D; and to determine the PK and pharmacodynamics (PD) of 4 weekly SC doses of PATAS in subjects with T2D. The secondary objectives of Part 2 of this study are to evaluate the potential effect of multiple SC doses of PATAS on markers of glycemic control, as measured by glucose levels, insulin levels, and other metabolomic biomarkers; and to characterize the adverse event (AE) profiles of the various dose levels of PATAS.
Phase 1
Waitlist Available
Medpace Clinical Pharmaology UnitVincent Marion, Ph.D.AdipoPharma LLC
Have you considered Symlin clinical trials? We made a collection of clinical trials featuring Symlin, we think they might fit your search criteria.Go to Trials
Image of The Worship Center Cristian Church in Birmingham, United States.

Black Impact for Heart Health

18+
Male
Birmingham, AL
The goal of this clinical trial is to evaluate the implementation and effectiveness of the Black Impact program-a church-based cardiovascular health (CVH) intervention-in Black men aged 35-70 who are at risk for heart disease, diabetes, obesity, and related conditions. The main questions this study aims to answer are: * Does participation in the Black Impact program improve cardiovascular health metrics (e.g., blood pressure, cholesterol, blood sugar) and health behaviors among Black men at The Worship Center Christian Church (TWC)? * What factors influence the adoption, delivery, and sustainability of the Black Impact program in a faith-based setting? Researchers will compare an immediate-start intervention group and a delayed-start (waitlist control) group to assess both short-term health outcomes and program implementation factors. Participants will: * Attend a 90-minute weekly session for 24 weeks, including 45 minutes of physical activity led by a certified trainer and 45 minutes of health education delivered by trained coaches. * Receive one-on-one support from a community health worker to reduce barriers to care and engage with primary care. * Complete biometric health screenings and surveys at baseline, 12 weeks, and 24 weeks to assess clinical and behavioral outcomes. * Use a smartwatch, blood pressure cuff, and other tools to track progress in real time. * Participate in exit focus groups or interviews to share feedback about the intervention. * A subset of TWC leaders and interventionists (N=15) will also be interviewed to assess implementation, resource needs, and sustainability. This study uses the RE-AIM framework to assess Reach, Effectiveness, Adoption, Implementation, and Maintenance, and aims to inform scalable strategies for improving CVH among Black men in trusted community settings.
Waitlist Available
Has No Placebo
The Worship Center Cristian Church
Have you considered Symlin clinical trials? We made a collection of clinical trials featuring Symlin, we think they might fit your search criteria.Go to Trials
Image of The University of North Carolina at Chapel Hill in Chapel Hill, United States.

Occupational Therapy for Type 1 Diabetes

2 - 99
All Sexes
Chapel Hill, NC
The goal of this clinical trial is to learn if the REAL-Fam occupational therapy intervention is feasible to study in a larger-scale randomized controlled trial. It will also seek to understand how the intervention influences how a rural family participates in and manages their child's type 1 diabetes, their family quality of life, and the child's health outcomes. The main questions it aims to answer are: * Primary Aim 1: Evaluate the recruitment capability, participant inclusion criteria, assessment selection and process, and data. * Primary Aim 2: Evaluate the participant acceptability of and interventionist fidelity to the intervention. * Secondary Aim: Evaluate families' preliminary outcomes to the REAL-Fam on family quality of life and participation, diabetes management self-efficacy, and child blood glucose stability. Researchers will compare the REAL-Fam intervention to the Attention Group to see if there are changes in family diabetes-related health routines and psychosocial aspects of managing a child's type 1 diabetes. Participants will: * Children will wear continuous glucose monitors for study period * Caregiver participants will complete baseline and post-intervention surveys * Intervention Group: engage in 12 audio/video telehealth sessions with REAL-Fam intervention * Attention Group: engage in 3 audio/video Zoom meetings without specialized services * Complete a post-study interview
Waitlist Available
Has No Placebo
The University of North Carolina at Chapel HillVanessa Jewell, PhDDexCom, Inc.
Have you considered Symlin clinical trials? We made a collection of clinical trials featuring Symlin, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security